InvestorsObserver
Sign Up Login

CCCC C4 Therapeutics Inc

$8.03 $0.00 (0.00%)
Add to Watchlist Compare
Overall

CCCC Stock Analysis Overview

What this means: InvestorsObserver gives C4 Therapeutics Inc (CCCC) an overall rank of 43, which is below average. C4 Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

CCCC Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

CCCC Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

CCCC Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

CCCC Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

CCCC Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

CCCC Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

CCCC Stock Analysis Overview

What this means: InvestorsObserver gives C4 Therapeutics Inc (CCCC) an overall rank of 43, which is below average. C4 Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CCCC report

CCCC Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

CCCC Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

CCCC Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

CCCC Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

CCCC Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

CCCC Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

C4 Therapeutics Inc (CCCC) Analyst Forecast

CCCC Price, Volume, Earnings, and Dividend Date

  • Last Price $8.03
  • Previous Close $8.03
  • Change $0.00
  • Open $7.51
  • Volume 532,300
  • Avg. Volume (100-day) 902,059
  • Market Cap 391,841,725
  • Days Range 7.35 - 8.08
  • 52-week Range 4.84 - 51.21
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/10/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 2.728
  • PEG Ratio —

C4 Therapeutics Inc (CCCC) Company Description

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

C4 Therapeutics Inc (CCCC) Stock Chart

View Interactive CCCC chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
F-Star Therapeutics Inc (FSTX) (FSTX) $6.30
Trevi Therapeutics Inc (TRVI) (TRVI) $2.92
Alaunos Therapeutics Inc (TCRT) (TCRT) $1.30
Omeros Corp (OMER) (OMER) $4.64
Point Biopharma Global Inc (PNT) (PNT) $7.28
Savara Inc (SVRA) (SVRA) $1.54
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $21.73
Chinook Therapeutics Inc (KDNY) (KDNY) $17.51
Aveo Pharmaceuticals (AVEO) (AVEO) $6.71
Adma Biologics (ADMA) (ADMA) $2.03